We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bayer’s investment unit Leaps by Bayer and Northpond Ventures led the $55m Series A funding round of cancer therapies developer Triumvira Immunologics.